Investigational drug · Phase 2
YH32367
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HER2-Positive Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "YH32367"
First trial start
2022
Aug 26, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YH32367", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2-Positive Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "YH32367" as an intervention, largest first.
- Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid TumorRecruiting
Yuhan CorporationIndustry
NCT05523947 · 147 participants (planned) · Start Aug 26, 2022 · Primary completion Mar 31, 2028
Drug: YH32367 · For: HER2-Positive Solid Tumor
Sites: Boston, Massachusetts; Nashville, Tennessee; Adelaide, Australia · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.